早期正电子发射断层扫描应答 adapted 治疗在 I 期和 II 期霍奇金淋巴瘤中的随机 EORTC/LYSA/FIL H10 试验最终结果
H10 随机试验纳入 1950 例 I/II 期霍奇金淋巴瘤患者,按 ABVD 两周期后早期 PET 应答调整治疗。ePET 阳性者换用 BEACOPPesc+INRT 较标准 ABVD+INRT 改善 5 年 PFS(90.6% vs 77.4%,HR 0.42);ePET 阴性者单用 ABVD 未能证明非劣效,省略 INRT 增加复发风险,尤其预后良好组。
要点
- ePET 阳性者换用 BEACOPPesc+INRT,5 年 PFS 90.6% vs 77.4%(HR 0.42,P=0.002)。
- ePET 阴性预后良好组单用 ABVD 的 5 年 PFS 87.1% vs 99.0%(HR 15.8)。
- ePET 阴性预后不良组单用 ABVD 的 5 年 PFS 89.6% vs 92.1%(HR 1.45,95%CI 0.8-2.5)。
核心结论
- I/II 期霍奇金淋巴瘤 ABVD 两周期后 PET 应答可指导早期治疗调整。
- ePET 阳性者换用 BEACOPPesc+INRT 显著改善 5 年 PFS。
- ePET 阴性者单用 ABVD 未能证明非劣效,省略 INRT 增加复发风险,尤其预后良好组。
研究设计与样本
- 随机试验评估 I/II 期霍奇金淋巴瘤按 ABVD 两周期后 ePET 调整治疗,分预后良好(F)与不良(U)组。
- 标准组无论 ePET 结果均接受 ABVD 后 INRT;实验组 ePET 阴性者仅 ABVD(非劣效设计),阳性者换用两周期 BEACOPPesc+INRT(优效设计)。
- 1950 例随机分组,1925 例接受 ePET,361 例(18.8%)为阳性;主要终点为无进展生存(PFS)。
主要发现
- ePET 阳性者 5 年 PFS 从标准 ABVD+INRT 的 77.4% 提高到 BEACOPPesc+INRT 的 90.6%(HR 0.42,95%CI 0.23-0.74,P=0.002)。
- ePET 阴性 F 组 5 年 PFS:ABVD+INRT 99.0% vs 单用 ABVD 87.1%(HR 15.8,95%CI 3.8-66.1),支持 ABVD+INRT。
- ePET 阴性 U 组 5 年 PFS:ABVD+INRT 92.1% vs 单用 ABVD 89.6%(HR 1.45,95%CI 0.8-2.5),支持 ABVD+INRT。
- F 组和 U 组均未能证明单用 ABVD 相对于联合模式治疗的非劣效性。
关键数值与推荐
- ePET 阳性:5 年 PFS 90.6%(BEACOPPesc+INRT)vs 77.4%(ABVD+INRT),HR 0.42(95%CI 0.23-0.74,P=0.002)。
- ePET 阴性 F 组:5 年 PFS 99.0%(ABVD+INRT)vs 87.1%(单用 ABVD),HR 15.8(95%CI 3.8-66.1)。
- ePET 阴性 U 组:5 年 PFS 92.1%(ABVD+INRT)vs 89.6%(单用 ABVD),HR 1.45(95%CI 0.8-2.5)。
临床怎么用
- I/II 期霍奇金淋巴瘤 ABVD 两周期后 ePET 阳性者,可换用 BEACOPPesc+INRT 以改善 5 年 PFS。
- ePET 阴性者单用 ABVD 未证明非劣效,省略 INRT 增加复发风险,尤其 F 组。
局限性
- F 组和 U 组均未能证明单用 ABVD 相对于联合模式治疗的非劣效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Patients who receive combined modality treatment for stage I and II Hodgkin lymphoma (HL) have an excellent outcome. Early response evaluation with positron emission tomography (PET) scan may improve selection of patients who need reduced or more intensive treatments. Methods We performed a randomized trial to evaluate treatment adaptation on the basis of early PET (ePET) after two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in previously untreated-according to European Organisation for Research and Treatment of Cancer criteria favorable (F) and unfavorable (U)-stage I and II HL. The standard arm consisted of ABVD followed by involved-node radiotherapy (INRT), regardless of ePET result. In the experimental arm, ePET-negative patients received ABVD only (noninferiority design), whereas ePET-positive patients switched to two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) and INRT (superiority design). Primary end point was progression-free survival (PFS). Results Of 1,950 randomly assigned patients, 1,925 received an ePET-361 patients (18.8%) were positive. In ePET-positive patients, 5-year PFS improved from 77.4% for standard ABVD + INRT to 90.6% for intensification to BEACOPPesc + INRT (hazard ratio [HR], 0.42; 95% CI, 0.23 to 0.74; P = .002). In ePET-negative patients, 5-year PFS rates in the F group were 99.0% versus 87.1% (HR, 15.8; 95% CI, 3.8 to 66.1) in favor of ABVD + INRT; the U group, 92.1% versus 89.6% (HR, 1.45; 95% CI, 0.8 to 2.5) in favor of ABVD + INRT. For both F and U groups, noninferiority of ABVD only compared with combined modality treatment could not be demonstrated. Conclusion In stage I and II HL, PET response after two cycles of ABVD allows for early treatment adaptation. When ePET is positive after two cycles of ABVD, switching to BEACOPPesc + INRT significantly improved 5-year PFS. In ePET-negative patients, noninferiority of ABVD only could not be demonstrated: risk of relapse is increased when INRT is omitted, especially in patients in the F group.
引用
- André MPE, Girinsky T, Federico M, et al. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2017. PMID: 28291393. doi:10.1200/JCO.2016.68.6394
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。